{
    "Trade/Device Name(s)": [
        "Contour NEXT EZ Blood Glucose Monitoring System"
    ],
    "Submitter Information": "Bayer Healthcare LLC., Diabetes Care",
    "510(k) Number": "K111268",
    "Predicate Device Reference 510(k) Number(s)": [
        "K062058"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LFR",
        "NBW",
        "JJX"
    ],
    "Summary Letter Date": "February 24, 2012",
    "Summary Letter Received Date": "February 27, 2012",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Whole blood",
        "Fresh fingertip capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Contour NEXT EZ Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Analyzer",
        "Test Strip",
        "Control Solution"
    ],
    "Document Summary": "FDA 510(k) summary for Contour NEXT EZ Blood Glucose Monitoring System, an OTC device for self-monitoring glucose in whole blood by persons with diabetes",
    "Indications for Use Summary": "OTC self-testing for quantitative measurement of glucose in whole blood from fresh fingertip capillary samples by single-patient use, aiding diabetes control monitoring; not for diagnosis or screening or use on neonates",
    "fda_folder": "Clinical Chemistry"
}